331. 特発性多中心性キャッスルマン病
[臨床試験数:30,薬物数:44(DrugBank:23),標的遺伝子数:30,標的パスウェイ数:148

Searched query = "Idiopathic multicentric castleman disease", "Castleman disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04585893
(ClinicalTrials.gov)
October 202010/9/2020Safety and Efficacy of Rituximab for Treatment of Multicentric Castleman Disease in MalawiLCCC 1950 - Rituximab for Multicentric Castleman Disease in Malawi, A Single-Arm Phase II Safety/Efficacy TrialMulticentric Castleman DiseaseDrug: Rituximab;Drug: EtoposideUNC Lineberger Comprehensive Cancer CenterFogarty International Center of the National Institute of HealthNot yet recruiting18 YearsN/AAll27Phase 2Malawi
2JPRN-jRCT2071190029
25/05/202009/10/2019Randomized, double-blind, placebo-controlled, parallel-group trial of sirolimus for tocilizumab-resistant idiopathic multicentric Castleman disease: Study protocol for clinical trial (SPIRIT Compliant)Randomized, double-blind, placebo-controlled, parallel-group trial of sirolimus for tocilizumab-resistant idiopathic multicentric Castleman disease: Study protocol for clinical trial (SPIRIT Compliant) idiopathic multicentric Castleman's disease
Castleman's disease
Treatment: Sirolimus 2 mg po once/day.
Control: Placebo given orally once daily
Kawakami AtsushiNULLRecruiting>= 18age oldNot applicableBoth20Phase 2Japan
3NCT03864419
(ClinicalTrials.gov)
October 24, 20191/3/2019Rituximab Hyaluronidase in Combination With Chemotherapy in Treating Aggressive B-cell Lymphoma in UgandaA Phase I Study of Subcutaneous Rituximab Hyaluronidase Combined With Local Standard-of-Care Chemotherapy for the Treatment of Burkitt Lymphoma, Diffuse Large B-Cell Lymphoma or as Monotherapy for Kaposi Sarcoma Herpesvirus Associated Multicentric Castleman Disease in Pediatrics and Adults in UgandaBurkitt Lymphoma;KSHV-associated Multicentric Castleman Disease;Diffuse Large B-Cell LymphomaBiological: Rituximab or Rituximab Hyaluronidase Human;Drug: Cyclophosphamide;Drug: Vincristine;Drug: Methotrexate;Drug: Doxorubicin;Drug: Doxorubicin Hydrochloride;Drug: Prednisone;Drug: EtoposideFred Hutchinson Cancer Research CenterNational Cancer Institute (NCI)Recruiting2 YearsN/AAll40Phase 1Uganda;United States
4NCT03933904
(ClinicalTrials.gov)
September 25, 201929/4/2019Sirolimus in Previously Treated Idiopathic Multicentric Castleman DiseaseA Phase II, Single-arm Open-label Multi-center Study of Sirolimus in Previously Treated Idiopathic Multicentric Castleman DiseaseCastleman Disease;Castleman's Disease, MulticentricDrug: SirolimusUniversity of PennsylvaniaNULLRecruiting18 Years80 YearsAll24Phase 2United States
5NCT03982771
(ClinicalTrials.gov)
January 1, 20193/5/2019BCD Regimen in Newly Diagnosed Idiopathic Multicentric Castleman's Disease (iMCD)Bortezomib, Cyclophosphamide and Dexamethasone (BCD) in Newly Diagnosed Idiopathic Multicentric Castleman's Disease (iMCD) : a Prospective, Single-center, Single-arm, Phase-II Pilot TrialIdiopathic Multicentric Castleman's DiseaseDrug: Bortezomib;Drug: Cyclophosphamide;Drug: DexamethasonPeking Union Medical College HospitalNULLRecruiting18 YearsN/AAll30Phase 2China
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT03043105
(ClinicalTrials.gov)
January 1, 201731/1/2017TCP Regimen in Newly Diagnosed MCD:a Prospective, Single-center, Single-arm, Phase-II Pilot TrialThalidomide, Cyclophosphamide and Prednisone in Newly Diagnosed Multicentric Castleman's Disease: a Prospective, Single-center, Single-arm, Phase-II Pilot TrialMulticentric Castleman DiseaseDrug: Thalidomide, cyclophosphamide and prednisonePeking Union Medical College HospitalNULLActive, not recruiting18 YearsN/AAll25Phase 2China
7NCT02228512
(ClinicalTrials.gov)
August 15, 201427/8/2014Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated LymphomasPhase I/II Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated Lymphomas (Primary Effusion Lymphoma and Large Cell Lymphoma Arising in KSHV-Associated Multicentric Castleman Disease)Large Cell Lymphoma Arising in KSHV-associated Multicentric Castleman Disease;Primary Effusion LymphomaDrug: Pomalidomide;Drug: Rituximab;Drug: Prednisone;Drug: Etoposide;Drug: Doxorubicin;Drug: Vincristine;Drug: CyclophosphamideNational Cancer Institute (NCI)NULLWithdrawn18 Years99 YearsAll0Phase 1;Phase 2United States
8NCT02080416
(ClinicalTrials.gov)
July 20144/3/2014Nelfinavir for the Treatment of Gammaherpesvirus-Related TumorsA Pilot Trial of Nelfinavir for the Lytic Activation and Treatment of Gammaherpesvirus-Related TumorsNon-Hodgkin Lymphoma;Hodgkin Lymphoma;Kaposi Sarcoma;Gastric Cancer;Nasopharyngeal Cancer;EBV;Castleman DiseaseDrug: NelfinavirSidney Kimmel Comprehensive Cancer CenterNULLTerminated18 YearsN/ABoth1Phase 0United States
9EUCTR2010-022837-27-GB
(EUCTR)
15/02/201301/08/2012A Study to Evaluate the Safety of Long-term Treatment with Siltuximab in Patients with Multicentric Castleman's DiseaseAn Open-label, Multicenter Study to Evaluate the Safety of Long-term Treatment with Siltuximab in Subjects with Multicentric Castleman's Disease Multicentric Castleman's Disease
MedDRA version: 14.1;Level: PT;Classification code 10050251;Term: Castleman's disease;System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
Janssen-Cilag International N.V.NULLNot Recruiting Female: yes
Male: yes
75Phase 2United States;Hong Kong;Taiwan;Spain;Israel;United Kingdom;Egypt;France;Canada;Belgium;Brazil;Singapore;Germany;Norway;New Zealand;China;Korea, Republic of
10EUCTR2010-022837-27-BE
(EUCTR)
17/12/201223/07/2012A Study to Evaluate the Safety of Long-term Treatment with Siltuximab in Patients with Multicentric Castleman's DiseaseAn Open-label, Multicenter Study to Evaluate the Safety of Long-term Treatment with Siltuximab in Subjects with Multicentric Castleman's Disease Multicentric Castleman's Disease
MedDRA version: 17.0;Level: PT;Classification code 10050251;Term: Castleman's disease;System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps);Therapeutic area: Diseases [C] - Cancer [C04]
Product Name: CNTO328
Product Code: CNTO328
Other descriptive name: SILTUXIMAB
Janssen-Cilag International N.V.NULLNot RecruitingFemale: yes
Male: yes
75Phase 2United States;Taiwan;Hong Kong;Spain;Israel;United Kingdom;Egypt;France;Canada;Belgium;Brazil;Singapore;Norway;Germany;New Zealand;China;Korea, Republic of
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
11EUCTR2010-022837-27-ES
(EUCTR)
29/11/201226/09/2012A Study to Evaluate the Safety of Long-term Treatment with Siltuximab in Patients with Multicentric Castleman's DiseaseAn Open-label, Multicenter Study to Evaluate the Safety of Long-term Treatment with Siltuximab in Subjects with Multicentric Castleman's Disease Multicentric Castleman's Disease
MedDRA version: 15.0;Level: PT;Classification code 10050251;Term: Castleman's disease;System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps);Therapeutic area: Diseases [C] - Cancer [C04]
Product Name: CNTO328
Product Code: CNTO328
INN or Proposed INN: NA
Other descriptive name: SILTUXIMAB
Janssen-Cilag International N.V.NULLNot RecruitingFemale: yes
Male: yes
80Phase 2United States;Hong Kong;Taiwan;Spain;Israel;United Kingdom;Egypt;France;Canada;Belgium;Brazil;Singapore;Germany;Norway;New Zealand;China;Korea, Republic of
12EUCTR2010-022837-27-DE
(EUCTR)
21/11/201219/09/2012A Study to Evaluate the Safety of Long-term Treatment with Siltuximab in Patients with Multicentric Castleman's DiseaseAn Open-label, Multicenter Study to Evaluate the Safety of Long-term Treatment with Siltuximab in Subjects with Multicentric Castleman's Disease Multicentric Castleman's Disease
MedDRA version: 17.0;Level: PT;Classification code 10050251;Term: Castleman's disease;System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps);Therapeutic area: Diseases [C] - Cancer [C04]
Product Name: CNTO328
Product Code: CNTO328
Other descriptive name: SILTUXIMAB
Janssen-Cilag International N.V.NULLNot RecruitingFemale: yes
Male: yes
75Phase 2United States;Taiwan;Hong Kong;Spain;Israel;United Kingdom;Egypt;France;Canada;Belgium;Brazil;Singapore;Norway;Germany;New Zealand;China;Korea, Republic of
13NCT01552434
(ClinicalTrials.gov)
March 16, 20127/3/2012Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign DiseaseA Phase I Trial of Bevacizumab, Temsirolimus Alone and in Combination With Valproic Acid, or Cetuximab in Patients With Advanced Malignancy and Other IndicationsAdvanced Malignant Neoplasm;Castleman Disease;Digestive System Carcinoma;Erdheim-Chester Disease;Lip and Oral Cavity Carcinoma;Lymphangioleiomyomatosis;Malignant Endocrine Neoplasm;Malignant Female Reproductive System Neoplasm;Malignant Male Reproductive System Neoplasm;Malignant Neoplasm;Malignant Respiratory Tract Neoplasm;Malignant Thoracic Neoplasm;Malignant Urinary System Neoplasm;Mesothelial Neoplasm;Metastatic Malignant Neoplasm;Metastatic Urothelial Carcinoma;Neurofibromatosis Type 2;Recurrent Adult Soft Tissue Sarcoma;Recurrent Breast Carcinoma;Recurrent Childhood Soft Tissue Sarcoma;Recurrent Digestive System Carcinoma;Recurrent Female Reproductive System Carcinoma;Recurrent Male Reproductive System Carcinoma;Recurrent Malignant Neoplasm;Recurrent Pharyngeal Carcinoma;Recurrent Thyroid Gland Carcinoma;Refractory Malignant Neoplasm;Soft Tissue Neoplasm;Stage III Breast Cancer AJCC v7;Stage III Pharyngeal Cancer;Stage IIIA Breast Cancer AJCC v7;Stage IIIB Breast Cancer AJCC v7;Stage IIIC Breast Cancer AJCC v7;Stage IV Breast Cancer AJCC v6 and v7;Stage IV Pharyngeal Cancer;Stage IVA Pharyngeal Cancer;Stage IVB Pharyngeal Cancer;Stage IVC Pharyngeal Cancer;Thyroid Gland NeoplasmBiological: Bevacizumab;Biological: Cetuximab;Other: Laboratory Biomarker Analysis;Other: Pharmacological Study;Drug: Temsirolimus;Drug: Valproic AcidM.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingN/AN/AAll216Phase 1United States
14NCT01441063
(ClinicalTrials.gov)
September 13, 201124/9/2011Tocilizumab for KSHV-Associated Multicentric Castleman DiseasePilot Study of Tocilizumab in Patients With Symptomatic Kaposi Sarcoma Herpesvirus (KSHV) - Associated Multicentric Castleman DiseaseCastleman Disease;Multicentric Castleman Disease;Giant Lymph Node HyperplasiaDrug: Zidovudine;Drug: Tocilizumab;Drug: Valganciclovir (VGC)National Cancer Institute (NCI)NULLCompleted18 YearsN/AAll8Phase 2United States
15NCT01400503
(ClinicalTrials.gov)
April 1, 201121/4/2011A Study to Evaluate the Safety of Long-term Treatment With Siltuximab in Patients With Multicentric Castleman's DiseaseAn Open-label, Multicenter Study to Evaluate the Safety of Long-term Treatment With Siltuximab in Subjects With Multicentric Castleman's DiseaseMulticentric Castleman's DiseaseDrug: SiltuximabJanssen Research & Development, LLCNULLCompleted18 YearsN/AAll60Phase 2United States;Belgium;Brazil;Canada;China;Egypt;France;Germany;Hong Kong;Israel;Korea, Republic of;New Zealand;Norway;Singapore;Spain;Taiwan;United Kingdom
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
16EUCTR2009-012380-34-GB
(EUCTR)
18/05/201024/09/2009A study of the safety and efficacy of CNTO328 in combination with best supportive care compared to best supportive care in patients with Multicentric Castleman's DiseaseA Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of CNTO 328 (Anti-IL-6 Monoclonal Antibody) Plus Best Supportive Care Compared With Best Supportive Care in Subjects With Multicentric Castleman’s Disease Multicentric Castleman's disease
MedDRA version: 14.1;Level: PT;Classification code 10050251;Term: Castleman's disease;System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Janssen-Cilag International N.V.NULLNot Recruiting Female: yes
Male: yes
78Phase 2United States;Hong Kong;Taiwan;Spain;Israel;Russian Federation;United Kingdom;India;France;Egypt;Hungary;Canada;Malaysia;Belgium;Brazil;Singapore;Australia;Netherlands;Germany;Norway;New Zealand;China;Korea, Republic of
17EUCTR2009-012380-34-NL
(EUCTR)
23/03/201021/10/2009A Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy andSafety of CNTO 328 (Anti-IL-6 Monoclonal Antibody) Plus Best Supportive CareCompared With Best Supportive Care in Subjects With Multicentric Castleman’sDiseaseA Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy andSafety of CNTO 328 (Anti-IL-6 Monoclonal Antibody) Plus Best Supportive CareCompared With Best Supportive Care in Subjects With Multicentric Castleman’sDisease Multicentric Castleman's disease
MedDRA version: 13.1;Level: PT;Classification code 10050251;Term: Castleman's disease;System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Product Name: CNTO328
Product Code: CNTO328
INN or Proposed INN: NA
Other descriptive name: Chimeric murine human anti-IL-6 monoclonal antibody
Janssen Biologics B.V.NULLNot RecruitingFemale: yes
Male: yes
78Phase 2France;Hungary;Spain;Belgium;Germany;Netherlands;United Kingdom
18EUCTR2009-012380-34-HU
(EUCTR)
18/03/201015/12/2009A Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy andSafety of CNTO 328 (Anti-IL-6 Monoclonal Antibody) Plus Best Supportive CareCompared With Best Supportive Care in Subjects With Multicentric Castleman’sDiseaseA Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy andSafety of CNTO 328 (Anti-IL-6 Monoclonal Antibody) Plus Best Supportive CareCompared With Best Supportive Care in Subjects With Multicentric Castleman’sDisease Multicentric Castleman's disease
MedDRA version: 13.1;Level: PT;Classification code 10050251;Term: Castleman's disease;System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Product Name: CNTO328
Product Code: CNTO328
INN or Proposed INN: NA
Other descriptive name: Chimeric murine human anti-IL-6 monoclonal antibody
Product Name: CNTO328
Product Code: CNTO328
INN or Proposed INN: NA
Other descriptive name: Chimeric murine human anti-IL-6 monoclonal antibody
Janssen Biologics BVNULLNot RecruitingFemale: yes
Male: yes
78Hungary;Germany;United Kingdom;Netherlands;Belgium;France;Spain
19NCT01024036
(ClinicalTrials.gov)
March 18, 201030/11/2009A Study to Evaluate the Efficacy and Safety of CNTO328 Plus Best Supportive Care in Multicentric Castleman's DiseaseA Randomized, Double Blind, Placebo Controlled Study to Assess the Efficacy and Safety of CNTO 328 (Anti IL 6 Monoclonal Antibody) Plus Best Supportive Care Compared With Best Supportive Care in Subjects With Multicentric Castleman's DiseaseMulticentric Castleman's DiseaseDrug: Siltuximab;Drug: Placebo;Drug: Best Supportive Care (BSC)Janssen Research & Development, LLCNULLCompleted18 YearsN/AAll79Phase 2United States;Australia;Belgium;Brazil;Canada;China;Egypt;France;Germany;Hong Kong;Hungary;India;Israel;Korea, Republic of;Malaysia;Netherlands;New Zealand;Norway;Russian Federation;Singapore;Spain;Taiwan;United Kingdom;Jordan;Poland
20EUCTR2009-012380-34-DE
(EUCTR)
27/01/201015/10/2009A study of the safety and efficacy of CNTO 328 in combination with best supportive care compared to best supportive care in patients with Multicentric Castleman's DiseaseA Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of CNTO 328 (Anti-IL-6 Monoclonal Antibody) Plus Best Supportive Care Compared With Best Supportive Care in Subjects With Multicentric Castleman’s Disease Multicentric Castleman's disease
MedDRA version: 14.1;Level: PT;Classification code 10050251;Term: Castleman's disease;System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Product Name: CNTO328
Product Code: CNTO328
INN or Proposed INN: NA
Other descriptive name: Chimeric murine human anti-IL-6 monoclonal antibody
Product Name: CNTO328
Product Code: CNTO328
INN or Proposed INN: NA
Other descriptive name: Chimeric murine human anti-IL-6 monoclonal antibody
Janssen-Cilag International N.V.NULLNot RecruitingFemale: yes
Male: yes
75United Kingdom;France;Hungary;Spain;Belgium;Netherlands;Germany
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
21EUCTR2009-012380-34-BE
(EUCTR)
26/01/201005/10/2009A study of the safety and efficacy of CNTO 328 in combination with best supportive care compared to best supportive care in patients with Multicentric Castleman's DiseaseA Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of CNTO 328 (Anti-IL-6 Monoclonal Antibody) Plus Best Supportive Care Compared With Best Supportive Care in Subjects With Multicentric Castleman’s Disease Multicentric Castleman's disease
MedDRA version: 14.1;Level: PT;Classification code 10050251;Term: Castleman's disease;System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Product Name: CNTO328
Product Code: CNTO328
INN or Proposed INN: NA
Other descriptive name: Chimeric murine human anti-IL-6 monoclonal antibody
Janssen-Cilag International N.V.NULLNot RecruitingFemale: yes
Male: yes
78Phase 2Hong Kong;United States;Taiwan;Israel;Russian Federation;United Kingdom;India;France;Egypt;Hungary;Canada;Malaysia;Belgium;Brazil;Singapore;Australia;Netherlands;Germany;Norway;New Zealand;China;Korea, Republic of;Spain
22EUCTR2009-012380-34-FR
(EUCTR)
21/01/201016/10/2009A Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy andSafety of CNTO 328 (Anti-IL-6 Monoclonal Antibody) Plus Best Supportive CareCompared With Best Supportive Care in Subjects With Multicentric Castleman’sDiseaseA Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy andSafety of CNTO 328 (Anti-IL-6 Monoclonal Antibody) Plus Best Supportive CareCompared With Best Supportive Care in Subjects With Multicentric Castleman’sDisease Multicentric Castleman's disease
MedDRA version: 12.0;Level: LLT;Classification code 10050251;Term: Castleman's disease
Product Name: CNTO328
Product Code: CNTO328
INN or Proposed INN: NA
Other descriptive name: Chimeric murine human anti-IL-6 monoclonal antibody
Centocor BVNULLNot RecruitingFemale: yes
Male: yes
75Phase 2France;Hungary;Spain;Belgium;Netherlands;Germany;United Kingdom
23EUCTR2009-012380-34-ES
(EUCTR)
21/12/200908/10/2009Estudio aleatorizado, doble ciego, controlado con placebo para valorar la eficacia y seguridad de CNTO 328 (anticuerpo monoclonal anti-IL-6) junto con la mejor terapia de soporte comparado con la mejor terapia de soporte, en sujetos con enfermedad de Castleman multicéntrica.A Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy andSafety of CNTO 328 (Anti-IL-6 Monoclonal Antibody) Plus Best Supportive Care Compared With Best Supportive Care in Subjects With Multicentric Castleman?sDiseaseEstudio aleatorizado, doble ciego, controlado con placebo para valorar la eficacia y seguridad de CNTO 328 (anticuerpo monoclonal anti-IL-6) junto con la mejor terapia de soporte comparado con la mejor terapia de soporte, en sujetos con enfermedad de Castleman multicéntrica.A Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy andSafety of CNTO 328 (Anti-IL-6 Monoclonal Antibody) Plus Best Supportive Care Compared With Best Supportive Care in Subjects With Multicentric Castleman?sDisease enfermedad de Castleman multicéntrica
MedDRA version: 12.0;Level: LLT;Classification code 10050251;Term: Castleman's disease
Product Name: CNTO328
Product Code: CNTO328
INN or Proposed INN: NA
Other descriptive name: Chimeric murine human anti-IL-6 monoclonal antibody
Product Name: CNTO328
Product Code: CNTO328
INN or Proposed INN: NA
Other descriptive name: Chimeric murine human anti-IL-6 monoclonal antibody
Centocor BVNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
75Hungary;Germany;United Kingdom;Netherlands;Belgium;France;Spain
24NCT00891280
(ClinicalTrials.gov)
February 200929/4/2009Dose-escalation Study of Oral CX-4945A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of CX-4945 Administered Orally to Patients With Advanced Solid Tumors, Castleman's Disease or Multiple MyelomaAdvanced Solid Tumors;Breast Cancer;Inflammatory Breast Cancer;Castleman's Disease;Multiple MyelomaDrug: CX-4945 oral formulationCylene PharmaceuticalsNULLRecruiting18 YearsN/ABoth55Phase 1United States
25NCT00361933
(ClinicalTrials.gov)
December 20088/8/2006Valganciclovir to Treat HHV-8 Associated Multicentric Castleman's DiseaseClinical and Virologic Response to HHV-8 Associated Multicentric Castleman's Disease to ValganciclovirGiant Lymph Node HyperplasiaDrug: ValganciclovirUniversity of WashingtonHoffmann-La RocheWithdrawn18 YearsN/AAll0Phase 4United States
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
26NCT01183598
(ClinicalTrials.gov)
August 200613/8/2010A Study to Provide RoActemra/Actemra (Tocilzumab) to Patients With Multicentric Castleman's Disease Who Demonstrated Benefit From Previous RoActemra/Actemra TreatmentProvision of Tocilizumab for Patients With Multicentric Castleman's Disease Who Have Demonstrated Benefit From Previous Tocilizumab TreatmentCastleman's DiseaseDrug: tocilizumab [RoActemra/Actemra]Hoffmann-La RocheNULLCompleted18 YearsN/ABoth3Phase 1United States
27NCT00412321
(ClinicalTrials.gov)
May 200515/12/2006A Safety and Efficacy Study of CNTO 328 in Patients With B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's DiseaseA Phase 1 Study of Multiple Intravenous Administrations of a Chimeric Antibody Against Interleukin-6 (CNTO 328) in Subjects With B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's DiseaseLymphoma, Non-Hodgkin;Multiple Myeloma;Giant Lymph Node HyperplasiaDrug: CNTO 328Centocor, Inc.NULLCompleted18 YearsN/ABoth67Phase 1United States
28NCT00092222
(ClinicalTrials.gov)
October 28, 200421/9/2004Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease ActivityTargeted Oncolytic Virotherapy and Natural History Study of KSHV-Associated Multicentric Castleman's Disease With Laboratory and Clinical Correlates of Disease ActivityLymphoproliferative Disorder;HHV-8;Malignancy;HIVDrug: Etoposide;Drug: Interferon-alpha;Drug: Rituximab;Drug: Zidovudine;Drug: Liposomal Doxorubicin;Drug: Bortezomib;Drug: Valganciclovir;Drug: Doxorubicin;Drug: Vincristine;Drug: Cyclophosphamide;Drug: Filgrastim (G-CSF);Drug: Prednisone;Drug: Sirolimus;Other: Observation OnlyNational Cancer Institute (NCI)NULLRecruiting12 YearsN/AAll72Phase 2United States
29NCT00127569
(ClinicalTrials.gov)
May 20034/8/2005Rituximab in the Treatment of HIV Associated Multicentric Castleman Disease Dependent on ChemotherapyMulticenter, Phase II Trial Assessing the Efficacy of Rituximab in HIV Infected Patients With Multicentric Castleman Disease Dependent on Chemotherapy (ANRS 117 Study, CastlemaB)HIV Infections;Giant Lymph Node HyperplasiaDrug: RituximabFrench National Agency for Research on AIDS and Viral HepatitisHoffmann-La RocheTerminated18 YearsN/ABoth25Phase 2NULL
30NCT00002652
(ClinicalTrials.gov)
May 19951/11/1999Suramin in Treating Patients With Refractory or Relapsed Multiple Myeloma or Castleman's DiseaseA PHASE II PILOT STUDY OF SURAMIN IN PREVIOUSLY TREATED PATIENTS WITH MULTIPLE MYELOMA AND PATIENTS WITH CASTLEMAN'S DISEASEMultiple Myeloma and Plasma Cell NeoplasmDrug: suraminUniversity of ArkansasNational Cancer Institute (NCI)Completed18 YearsN/ABothPhase 2United States